Dissertation Submitted to the Tamil Nadu Dr. M.G.R. Medical University
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Centre for Reviews and Dissemination
Management of acne Lehmann H P, Andrews J S, Robinson K A, Holloway V L, Goodman S N Authors' objectives To provide a comprehensive review on the management of acne. Searching The search utilised several electronic databases from inception to 1999, including the CENTRAL Register in the Cochrane Library, MEDLINE, OLDMEDLINE (from 1960 to 1965), EMBASE, CINAHL and PsycINFO amongst others. Details of the searches were given in the report. In addition, the reference lists from key articles were checked and key experts were consulted. Only full articles published in English were eligible for the review. Study selection Study designs of evaluations included in the review Only randomised controlled trials (RCTs) or quasi-RCTs were considered for the review. There were 259 (94%) studies of a parallel-group design, 15 (5%) crossover, 30 (11%) 'split-face', and 22 (8%) parallel studies with matched controls. Specific interventions included in the review Studies of first-, second- and third-line treatments for acne were eligible for inclusion in the review. The included studies were of 140 different treatments, which were classified as: cleansers, keratolytics, topical antibacterials, keratolytic/topical antibacterial combinations, topical retinoids, topical antibacterial/retinoid combinations, oral antibacterials, oral antibacterial/keratolytics, oral antibacterial/topical retinoids, oral retinoids, anti-androgens and other. All individual treatments are listed in the review. No single control intervention was specified as an inclusion criterion; 250 different pairwise comparisons were included in the review. Participants included in the review Patients with acne were included in the review. Studies of patients with complicating co-morbidities such as endocrinopathies, and specifically, chloracne, rosacea, acne venanta, acne fulminans and acne necroticans, were excluded. -
NG198 Evidence Review F2
FINAL Management options for moderate to severe acne – pairwise comparisons GRADE tables for review question: What is the effectiveness and acceptability of interventions for the treatment of moderate to severe acne (side effects and participant reported improvement)? Oral antibiotics Table 5: Clinical evidence profile for comparison of oral antibiotic versus placebo in participants with moderate to severe acne Quality assessment No of patients Effect Importanc Quality e No of Risk of Other Oral Placeb Relative Design Inconsistency Indirectness Imprecision Absolute studies bias considerations antibiotic o (95% CI) Skin irritation - Minocycline versus placebo 11 randomised serious7 no serious no serious very serious8 none 5/119 1/55 RR 2.31 (0.28 to 24 more per 1000 (from 13 ⊕ΟΟΟ CRITICAL trials inconsistency indirectness (4.2%) (1.8%) 19.31) fewer to 333 more) VERY LOW GI side effects 51,2,3,4,5 randomised very serious10 no serious very serious8 none 82/1543 41/1177 RR 1.11 (0.62 to 4 more per 1000 (from 13 ⊕ΟΟΟ CRITICAL trials serious9 indirectness (5.3%) (3.5%) 2) fewer to 35 more) VERY LOW Thrush / candiasis - Sarecyline versus placebo 24,5 randomised serious7 no serious no serious serious11 none 4/994 0/996 Peto OR 7.44 - ⊕⊕ΟΟ CRITICAL trials inconsistency indirectness (0.4%) (0%) (1.05 to 52.86) LOW Patient reported improvement - Tetracycline versus placebo 16 randomised very no serious no serious no serious none 21/29 1/29 RR 21 (3.02 to 690 more per 1000 (from ⊕⊕ΟΟ CRITICAL trials serious9 inconsistency indirectness imprecision (72.4%) (3.4%) 145.98) 70 more to 1000 more) LOW CI: confidence interval; GI: gastrointestinal; POR: peto odds ratio; RR: risk ratio 1 Stewart 2006 Acne vulgaris: evidence reviews for management options for moderate to severe acne – pairwise comparisons FINAL (June 2021) 143 FINAL Management options for moderate to severe acne – pairwise comparisons 2 Dubertret 2003 3 Leyden 2018 4 Moore 2018 (SC1401) 5 Moore 2018 (SC1402) 6 Braathen 1984 7 Overall risk of bias judgement: serious risk of bias. -
Copyrighted Material
1 Index Note: Page numbers in italics refer to figures, those in bold refer to tables and boxes. References are to pages within chapters, thus 58.10 is page 10 of Chapter 58. A definition 87.2 congenital ichthyoses 65.38–9 differential diagnosis 90.62 A fibres 85.1, 85.2 dermatomyositis association 88.21 discoid lupus erythematosus occupational 90.56–9 α-adrenoceptor agonists 106.8 differential diagnosis 87.5 treatment 89.41 chemical origin 130.10–12 abacavir disease course 87.5 hand eczema treatment 39.18 clinical features 90.58 drug eruptions 31.18 drug-induced 87.4 hidradenitis suppurativa management definition 90.56 HLA allele association 12.5 endocrine disorder skin signs 149.10, 92.10 differential diagnosis 90.57 hypersensitivity 119.6 149.11 keratitis–ichthyosis–deafness syndrome epidemiology 90.58 pharmacological hypersensitivity 31.10– epidemiology 87.3 treatment 65.32 investigations 90.58–9 11 familial 87.4 keratoacanthoma treatment 142.36 management 90.59 ABCA12 gene mutations 65.7 familial partial lipodystrophy neutral lipid storage disease with papular elastorrhexis differential ABCC6 gene mutations 72.27, 72.30 association 74.2 ichthyosis treatment 65.33 diagnosis 96.30 ABCC11 gene mutations 94.16 generalized 87.4 pityriasis rubra pilaris treatment 36.5, penile 111.19 abdominal wall, lymphoedema 105.20–1 genital 111.27 36.6 photodynamic therapy 22.7 ABHD5 gene mutations 65.32 HIV infection 31.12 psoriasis pomade 90.17 abrasions, sports injuries 123.16 investigations 87.5 generalized pustular 35.37 prepubertal 90.59–64 Abrikossoff -
A Comprehensive Review of Acne Vulgaris AK Mohiuddin1* 1Department of Pharmacy, World University of Bangladesh
Symbiosis ISSN Online: 2378-1726 www.symbiosisonlinepublishing.com Review Article Clinical Research in Dermatology: Open Access Open Access A Comprehensive Review of Acne Vulgaris AK Mohiuddin1* 1Department of Pharmacy, World University of Bangladesh Received: May 25, 2019; Accepted: June 6, 2019; Published: June 17, 2019 *Corresponding author: AK Mohiuddin, Assistant Professor, Department of Pharmacy, World University of Bangladesh, 151/8, Green Road, Dhanmondi, Dhaka – 1205, Bangladesh. E-mail: [email protected]; Orcid Id: https://orcid.org/0000-0003-1596-9757. Abstract Acne, also known as acne vulgaris (AV), is a long-term skin disease that occurs when hair follicles are clogged with dead skin cells and oil from the skin. It is characterized by blackheads or whiteheads, pimples, oily skin, and possible scarring. An intact stratum corneum and barrier, normal natural moisturizing factor and hyaluronic acid levels, normal Aquaporin-3 (AQP3) expression (localized at the basal lateral membranes of collecting duct cells in the kidney), and balanced sebum secretion are qualities of the skin that fall in the middle of the oily–dry spectrum. Patients rarely, if ever, complain about reduced sebum production, but elevated sebum production, yielding oily skin that can be a precursor to acne, is a common Propionibacterium acnes in adolescence, under the complaint. Several factors are known to influence sebum production. AV is mostly triggered by impact,influence as of sebum normal levels circulating are usually dehydroepiandrosterone low in childhood, rise (DHEA). in the middle-to-late It is a very common teen years, skin disorder and remain which stable can presentinto the withseventh inflammatory and eighth and decades non- untilinflammatory endogenous lesions androgen chiefly synthesis on the face dwindles. -
Pairwise Comparisons
National Institute for Health and Care Excellence Final Acne vulgaris: management [E2] Management options for mild to moderate acne – pairwise comparisons NG198 Evidence review underpinning recommendations 1.5.1, 1.5.2 and 1.5.5 to 1.5.14 (excluding 1.5.6 which is underpinned by evidence review L, 1.5.10 and bullet points 2 and 3 of recommendation 1.5.12 which are underpinned by evidence review F1 and 3 research recommendations in the NICE guideline - see evidence review E1 for the committee’s discussion of the evidence) June 2021 Final These evidence reviews were developed by the National Guideline Alliance which is a part of the Royal College of Obstetricians and Gynaecologists FINAL Error! No text of specified style in document. Disclaimer The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, professionals are expected to take this guideline fully into account, alongside the individual needs, preferences and values of their patients or service users. The recommendations in this guideline are not mandatory and the guideline does not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or their carer or guardian. Local commissioners and/or providers have a responsibility to enable the guideline to be applied when individual health professionals and their patients or service users wish to use it. They should do so in the context of local and national priorities for funding and developing services, and in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. -
Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0 -
Environmental Health Criteria 242
INTERNATIONAL PROGRAMME ON CHEMICAL SAFETY Environmental Health Criteria 242 DERMAL EXPOSURE IOMC INTER-ORGANIZATION PROGRAMME FOR THE SOUND MANAGEMENT OF CHEMICALS A cooperative agreement among FAO, ILO, UNDP, UNEP, UNIDO, UNITAR, WHO, World Bank and OECD This report contains the collective views of an international group of experts and does not necessarily represent the decisions or the stated policy of the World Health Organization The International Programme on Chemical Safety (IPCS) was established in 1980. The overall objec- tives of the IPCS are to establish the scientific basis for assessment of the risk to human health and the environment from exposure to chemicals, through international peer review processes, as a prerequi- site for the promotion of chemical safety, and to provide technical assistance in strengthening national capacities for the sound management of chemicals. This publication was developed in the IOMC context. The contents do not necessarily reflect the views or stated policies of individual IOMC Participating Organizations. The Inter-Organization Programme for the Sound Management of Chemicals (IOMC) was established in 1995 following recommendations made by the 1992 UN Conference on Environment and Development to strengthen cooperation and increase international coordination in the field of chemical safety. The Participating Organizations are: FAO, ILO, UNDP, UNEP, UNIDO, UNITAR, WHO, World Bank and OECD. The purpose of the IOMC is to promote coordination of the policies and activities pursued by the Participating Organizations, jointly or separately, to achieve the sound management of chemicals in relation to human health and the environment. WHO Library Cataloguing-in-Publication Data Dermal exposure. (Environmental health criteria ; 242) 1.Hazardous Substances - poisoning. -
12.2% 116000 125M Top 1% 154 4300
We are IntechOpen, the world’s leading publisher of Open Access books Built by scientists, for scientists 4,300 116,000 125M Open access books available International authors and editors Downloads Our authors are among the 154 TOP 1% 12.2% Countries delivered to most cited scientists Contributors from top 500 universities Selection of our books indexed in the Book Citation Index in Web of Science™ Core Collection (BKCI) Interested in publishing with us? Contact [email protected] Numbers displayed above are based on latest data collected. For more information visit www.intechopen.com ProvisionalChapter chapter 4 Occupational Acne Occupational Acne Betul Demir and Demet Cicek Betul Demir and Demet Cicek Additional information is available at the end of the chapter Additional information is available at the end of the chapter http://dx.doi.org/10.5772/64905 Abstract Occupational and environmental acne is a dermatological disorder associated with industrial exposure. Polyhalogenated hydrocarbons, coal tar and products, petrol, and other physical, chemical, and environmental agents are suggested to play a role in the etiology of occupational acne. The people working in the field of machine, chemistry, and electrical industry are at high risk. The various occupational acne includes chloracne, coal tar, and oil acne. The most common type in clinic is the comedones, and it is also seen as papule, pustule, and cystic lesions. Histopathological examination shows epidermal hyperplasia, while follicular and sebaceous glands are replaced by keratinized epidermal cells. Topical or oral retinoic acids and oral antibiotics could be used in treatment. The improvement in working conditions, taking preventive measures, and education of the workers could eliminate occupational acne as a problem. -
Acne Protection: Measures and Miseries
Vol 8, Issue 1, 2020 ISSN - 2347-5536 Review Article ACNE PROTECTION: MEASURES AND MISERIES ABDUL KADER MOHIUDDIN* Secretary and Treasurer, Dr. M. Nasirullah Memorial Trust, Tejgaon, Dhaka 1215, Bangladesh. Email: [email protected] Received: 14 October 2019, Revised and Accepted: 23 December 2019 ABSTRACT Acne, also known as acne vulgaris (AV), is a long-term skin disease that occurs when hair follicles are clogged with dead skin cells and oil from the skin. It is characterized by blackheads or whiteheads, pimples, oily skin, and possible scarring. An intact stratum corneum and barrier, normal natural moisturizing factor and hyaluronic acid levels, normal Aquaporin-3 expression (localized at the basal lateral membranes of collecting duct cells in the kidney), and balanced sebum secretion are qualities of the skin that fall in the middle of the oily-dry spectrum. Patients rarely, if ever, complain about reduced sebum production, but elevated sebum production, yielding oily skin that can be a precursor to acne, is a common complaint. Several factors are known to influence sebum production. AV is mostly triggered by Propionibacterium acnes in adolescence, under the influence of normal circulating dehydroepiandrosterone (DHEA). It is a very common skin disorder which can present with inflammatory and non-inflammatory lesions chiefly on the face but can also occur on the upper arms, trunk, and back. Age, in particular, has a significant and well-known impact, as sebum levels are usually low in childhood, rise in the middle to late teen years, and remain stable into the seventh and eighth decades until endogenous androgen synthesis dwindles. -
Tissue Liver X-Receptor Alpha (Lxrα) Level in Acne Vulgaris
TISSUE LIVER X-RECEPTOR ALPHA (LXRα) LEVEL IN ACNE VULGARIS Thesis Submitted for the fulfillment of Master Degree in Dermatology and Venereology BY Eman Abdelhamed Aly Nada (M.B.B.Ch) Supervisors Dr. Shereen Osama Tawfic Assistant prof.of Dermatology Faculty of Medicine Cairo University Dr. Marwa Ahmed Ezzat Lecturer of Dermatology Faculty of Medicine Cairo University Dr. Olfat Gamil Shaker Professor of Medical Biochemistry Faculty of Medicine Cairo University Faculty of Medicine Cairo University 2012 1 Acknowledgment First and foremost, I am thankful to God, for without his help I could not finish this work. I would like to express my sincere gratitude and appreciation to Dr. Shereen Osama Tawfic, Assistant Professor of Dermatology, Faculty of Medicine, Cairo University, for giving me the honor for working under her supervision and for her great support and stimulating views. Special thanks and deepest gratitude to Dr. Marwa Ahmed Ezzat, Lecturer of Dermatology, Faculty of Medicine, Cairo University, for her advice, support and encouragement all the time for a better performance. I am deeply thankful to Prof. Dr. Olfat Gamil Shaker, Professor of Medical Biochemistry, Faculty of Medicine, Cairo University for her sincere scientific and moral help in accomplishing the practical part of this study. I would like to extend my warmest gratitude to Prof. Dr. Manal Abdelwahed Bosseila, Professor of Dermatology, Faculty of Medicine, Cairo University, whose hard and faithful efforts have helped me to do this work. Furthermore, I would like to thank my family who stood behind me to finish this work and for their great support to me. -
NG198 Evidence Review F1
FINAL Management options for people with moderate to severe acne vulgaris - network meta-analyses Clinical studies The excluded studies list below relates to all evidence reviews that used the same search output and these are studies that are excluded from all of the following reviews: mild-to- moderate NMA, moderate-to-severe NMA, mild-to-moderate pairwise and moderate-to- severe pairwise reports, as well as from refractory acne, maintenance of acne and polycystic ovary syndrome reports. Table 24: Excluded clinical studies and reasons for their exclusion Reference Reason for exclusion Abbasi, M. A. K., A., Aziz ur, Rehman, Saleem, H.,Jahangir, S. No relevant study M.,Siddiqui, S. Z.,Ahmad, V. U.Preparation of new formulations of population - sample anti-acne creams and their efficacy. 2010. African Journal of includes people with mild Pharmacy and Pharmacology to severe acne and study is not relevant for PCOS, maintenance or refractory treatments Abdel Hay, R. H., R.,Abdel Hady, M.,Saleh, N.Clinical and Reported outcomes dermoscopic evaluation of combined (salicylic acid 20% and azelaic relevant for the network acid 20%) versus trichloroacetic acid 25% chemical peel in acne: an meta-analysis but not in RCT. 2019. Journal of Dermatological Treatment enough detail to include in the analysis. Outcomes were not relevant for pairwise comparisons - including PCOS, maintenance and refractory treatments Abdel Meguid, A. M. A. E. A. A., D.,Omar, H.Trichloroacetic acid Reported outcomes versus salicylic acid in the treatment of acne vulgaris in dark-skinned relevant for the network patients. 2015. Dermatologic Surgery meta-analysis but not in enough detail to include in the analysis. -
Management of Acne
Review CMAJ Management of acne John Kraft MD, Anatoli Freiman MD cne vulgaris has a substantial impact on a patient’s Key points quality of life, affecting both self-esteem and psychoso- cial development.1 Patients and physicians are faced • Effective therapies for acne target one or more pathways A in the pathogenesis of acne, and combination therapy with many over-the-counter and prescription acne treatments, gives better results than monotherapy. and choosing the most effective therapy can be confusing. • Topical therapies are the standard of care for mild to In this article, we outline a practical approach to managing moderate acne. acne. We focus on the assessment of acne, use of topical • Systemic therapies are usually reserved for moderate or treatments and the role of systemic therapy in treating acne. severe acne, with a response to oral antibiotics taking up Acne is an inflammatory disorder of pilosebaceous units to six weeks. and is prevalent in adolescence. The characteristic lesions are • Hormonal therapies provide effective second-line open (black) and closed (white) comedones, inflammatory treatment in women with acne, regardless of the presence papules, pustules, nodules and cysts, which may lead to scar- or absence of androgen excess. ring and pigmentary changes (Figures 1 to 4). The pathogene- sis of acne is multifactorial and includes abnormal follicular keratinization, increased production of sebum secondary to ing and follicle-stimulating hormone levels.5 Pelvic ultra- hyperandrogenism, proliferation of Propionibacterium acnes sonography may show the presence of polycystic ovaries.5 In and inflammation.2,3 prepubertal children with acne, signs of hyperandrogenism Lesions occur primarily on the face, neck, upper back and include early-onset accelerated growth, pubic or axillary hair, chest.4 When assessing the severity of the acne, one needs to body odour, genital maturation and advanced bone age.